Dr Reddy’s Laboratories has launched lamotrigine extended-release tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg) a therapeutic equivalent generic version of Lamictal XR (lamotrigine) in the US market, following the approval by the United States Food & Drug Administration (FDA) of its ANDA for Lamotrigine XR tablets.
The Lamictal XR brand and generic had combined US sales of approximately $300.5 million MAT for the most recent twelve months ending in April 2013 according to IMS Health.
Dr Reddy’s lamotrigine XR tablets 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg are available as unit of use bottles of 30s.
Dr Reddy’s Laboratories Ltd. is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.